REMS For Qsymia Limits Distribution, But Vivus To Explore Expanding Access
Executive Summary
Qsymia will launch through certified mail-order pharmacies, but FDA has asked the sponsor to look for ways to expand into the retail space with pharmacies that can meet requirements for distributing patient risk information and keeping track of prescribers.
You may also be interested in...
Women’s Intuition: What Approval Of Sprout’s Addyi Means For Sponsors
Filing for a drug with questionable risk-benefit profile was saved by a trial protocol redesign, strict safety labeling for a narrow indication, a REMS, patient mobilization and plenty of postmarketing studies. Trial period echoes FDA’s approach with a similar sector of lifestyle drug: obesity.
Specialty Pharmacies Could Be Selling Point If FDA Approves Tasimelteon
A Nov. 14 advisory committee gave near-unanimous support for Vanda’s sleep disorder drug on questions about its indication, endpoints, efficacy and safety.
With Another Push From Eisai, Can Arena’s Belviq Be A Blockbuster?
The Japanese pharma has expanded its collaboration with Arena for the obesity treatment Belviq, but the drug is off to a slow start in a market full of non-starters.